Vaxart, Inc. · OTC:VXRT
Vaxart — Society of Mucosal Immunology (July 2022)
17 slides from Vaxart's conference presentation, Jul 16, 2022
Slide 1: Oral Tablet Vaccination to SARS-CoV-2 Induces Pan-coronavirus Nasal IgA Responses in Humans
Oral Tablet Vaccination to SARS-CoV-2 Induces Pan-coronavirus Nasal IgA Responses in Humans Dr. Sean N. Tucker Vaxart Society of Mucosal Immunology 1
Slide 2: Forward looking statement
Forward looking statement This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this presentation regarding Vaxart’s strategy, prospects, plans and objectives, results from precli
Slide 3: Goal: Develop a simple vaccine format with significant impact on global protection
Goal: Develop a simple vaccine format that can have a significant impact on global vaccine protection and transmission Vaccine as a pill + Ease of distribution and storage Potentially more protective than injectable vaccines Convenient mode of administration, rapid and painless 3
Slide 4: IgA is very potent molecule in the fight against infectious disease
IgA is very potent molecule in the fight against infectious disease Inhibition of transmission and viral shedding via mucosal IgA § Reduced viral shedding by oral immunization in a human challenge study 1 § Breast Milk IgA blocks norovirus diarrheal decrease in infants 2 § Transmission blocking: Muc
Slide 5: Vaxart Solution: Intestinal Delivery + Targeted Immune Activation
Vaxart Solution: Intestinal Delivery + Targeted Immune Activation: Non-replicating vector with molecular adjuvant Key Issues to solve: 1. Replicating oral vaccines don’t work well in the developing world 2. Protein delivered to the intestine is treated like food Room-temperature stable ANTIGEN COVID
Slide 6: Expression of protein antigen in the same cell as the dsRNA creates specific immune response
Expression of protein antigen in exactly the same cell as the dsRNA (immune activator) creates a highly specific immune response Epithelial cell expressing antigen and dsRNA Room-temperature stable enteric-coated tablets 6
Slide 7: Oral Tablet Difference: cross-reactive and potent mucosal immune and systemic responses
Oral Tablet Difference: cross-reactive and potent mucosal immune and systemic responses Rapid Emergence of New SARS-CoV-2 Strains Oral Tablet is different § Cross-reactive immune responses § Tablets rather than injections IgA Distribution & Vaccine Administration Development We are currently chasing
Slide 8: Human Influenza Challenge Study: Challenge after 90 days
Human Influenza Challenge Study: Challenge after 90 days • A single dose administration of one of the following: • Arm 1: VXA-A1.1 oral vaccine + placebo IM injection (n=60+extra) • Arm 2: QIV injection + oral placebo tablet (n=60+extra) • Arm 3: Placebo IM injection + oral placebo tablet (n=30+extr
Slide 9: Demonstration of Efficacy – Respiratory Virus Challenge in Humans
Demonstration of Efficacy – Respiratory Virus Challenge in Humans Oral Vaccine Candidate protected against influenza infection as well as market leading injected vaccine after influenza challenge Reduced Infection Rates Trending Superior to Fluzone § Both vaccines protected against 80% Infection Rat
Slide 10: Vaxart Has Two Clinical COVID-19 Vaccine Candidates
Vaxart Has Two Clinical COVID-19 Vaccine Candidates VXA-CoV2-1.1-S (Expresses only S): phase II study ongoing VXA-CoV2-1 (Expresses S+ N): completed phase I 10
Slide 11: VXA-Cov2-1 Human Results
VXA-Cov2-1 Human Results Phase I study results – rAd-S+N construct § Small study (N=35, most subjects only given one immunization) – Well tolerated – Very robust, cross-reactive T cell response – IgA responses in the serum, saliva, and nasal against SARS-Cov-2 S protein 11
Slide 12: Oral vaccine candidate generates robust CD8 T cell responses
Vaxart’s Oral Vaccine candidate generates robust CD8 T cell responses – Compares favorably to the mRNA vaccines Induction of T cells responses measured 7 days after the first dose. Increase over day 1 for IFN-g, TNFa and CD107a are shown 6 Pfizer % CD8+ lymphocytes Moderna 4 Vaxart 2 Frozen PBMC sam
Slide 13: VXA-CoV2-1 Induces Cross reactive and Long-Lasting Nasal IgA
VXA-CoV2-1 Induces Cross reactive and Long-Lasting Nasal IgA Nasal IgA responses highly cross reactive against all coronaviruses § 46% of subjects had a 1.5 fold increase or better against SARS-CoV2-S which also induced increased antibody responses to every Coronavirus tested Cross Reactivity Longev
Slide 14: VXA-COV2-1 elicits IgA of a higher neutralizing ability than natural infection
VXA-COV2-1 elicits IgA of a higher neutralizing ability than natural infection Nasal Saliva nAb measured by sVNT assay Johnson, et al, Biorxiv, 2022 14 14
Slide 15: Summary
Summary – Vaxart oral tablet platform created a protective responses against a respiratory pathogen, with significant improvement against viral shedding following challenge compared to an injected vaccine – SARS-CoV-2 indication - testing two different candidates – First clinical trial with the vacc
Slide 16: Acknowledgements and Thanks
Acknowledgements and Thanks § Vaxart Research and Clinical • Duke University – Susan Johnson • Stephanie Langel – Molly Braun • John Hopkins University – Emery Dora • Bryan Patenaude • Jeromie Ballreich – Becca Flitter • Stanford University – Nadine Peinovich • David McIiwain – Clarissa Martinez • M
Slide 17: Backup slides
Backup slides Oh nn |||